Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Retatrutide shows potential for greater efficacy through triple-agonism but awaits Phase 3 results Best For Recommendations# Currently Available Treatment# Recommendation : Tirzepatide Reason : FDA-approved and commercially available as Mounjaro/Zepbound with established dosing protocols and post-market safety data Maximum Weight Loss Potential# Recommendation : Retatrutide Reason : Phase 2 data showed 24.2% weight loss at 48 weeks, exceeding tirzepatide's results, though Phase 3 confirmation is pending Non-Alcoholic Fatty Liver Disease# Recommendation : Retatrutide Reason : Glucagon receptor agonism directly promotes hepatic fat oxidation, showing up to 82% liver fat reduction in trials Type 2 Diabetes Management# Recommendation : Tirzepatide Reason : Proven HbA1c reduction with FDA approval specifically for glycemic control in type 2 diabetes Further Reading# Which Is Better For
It is not a GHRH analog it is a ghrelin mimetic, meaning it binds the ghrelin receptor (the same receptor activated by the hunger hormone)
If a woman on a GLP-1 medication is losing hair, the cause is usually rapid weight loss combined with iron, protein, or zinc insufficiency, not a missing transdermal compound
Your claim would generally target the company, not the prescribing physician, unless theres clear evidence of medical negligence
Some key health indicators are likely to improve on GLP-1s
US$ 24.63
US$ 24.72
US$ 29.89
